autophagy-lysosomal-alzheimers

Autophagy-Lysosomal Pathway in Alzheimer's Disease

Introduction

[Autophagy](/entities/autophagy) (meaning "self-eating") is a cellular degradation process that maintains neuronal homeostasis by removing damaged mitochondria (mitophagy), clearing protein aggregates, eliminating intracellular pathogens, and maintaining cellular homeostasis[@nixon2013]. The autophagy-lysosomal pathway is essential for neuronal survival due to the post-mitotic nature of neurons, which cannot dilute damaged components through cell division[@nixon2008].

In AD, autophagy-lysosomal function is impaired at multiple levels, contributing to the accumulation of [amyloid-beta](/proteins/amyloid-beta) (Aβ) and [tau](/proteins/tau) aggregates[@ballabio2009]. This impairment creates a vicious cycle where reduced autophagic clearance leads to toxic protein accumulation, which further disrupts cellular degradation pathways[@boland2008].

Key Mechanisms

1. Autophagy Initiation Dysregulation

Autophagy is initiated by the ULK1 complex and Beclin-1[@nixon2008]. In AD, multiple components of this initiation machinery are dysregulated:

...

Autophagy-Lysosomal Pathway in Alzheimer's Disease

Introduction

[Autophagy](/entities/autophagy) (meaning "self-eating") is a cellular degradation process that maintains neuronal homeostasis by removing damaged mitochondria (mitophagy), clearing protein aggregates, eliminating intracellular pathogens, and maintaining cellular homeostasis[@nixon2013]. The autophagy-lysosomal pathway is essential for neuronal survival due to the post-mitotic nature of neurons, which cannot dilute damaged components through cell division[@nixon2008].

In AD, autophagy-lysosomal function is impaired at multiple levels, contributing to the accumulation of [amyloid-beta](/proteins/amyloid-beta) (Aβ) and [tau](/proteins/tau) aggregates[@ballabio2009]. This impairment creates a vicious cycle where reduced autophagic clearance leads to toxic protein accumulation, which further disrupts cellular degradation pathways[@boland2008].

Key Mechanisms

1. Autophagy Initiation Dysregulation

Autophagy is initiated by the ULK1 complex and Beclin-1[@nixon2008]. In AD, multiple components of this initiation machinery are dysregulated:

• Beclin-1 reduction: Beclin-1 levels are significantly reduced in AD brain, impairing the nucleation step of autophagosome formation[@boland2008]
• ULK1 complex impairment: ULK1 complex signaling is compromised due to aberrant AMPK and mTOR regulation[@kim2011]
• mTOR dysregulation: [mTOR](/entities/mtor) overactivation phosphorylates and inhibits ULK1, preventing autophagy initiation[@saxton2017]
• Aβ interference: [Aβ](/proteins/amyloid-beta) oligomers directly interfere with autophagy initiation through multiple mechanisms[@matrone2019]
• TRIM22 scaffolding: TRIM22 functions as a scaffold protein for autophagy initiation by binding Beclin-1[@park2024]
• AMBRA1 regulation: AMBRA1 plays a critical role in mitophagy regulation[@ambra2024]
• Therapeutic activation: Magnolol activates the AMPK/mTOR/ULK1 pathway to restore autophagy in AD models[@wang2023]

The reduction in Beclin-1 creates a bottleneck in autophagosome nucleation, while mTOR hyperactivation prevents the ULK1 complex from initiating autophagy despite cellular stress signals[@bento2016].

2. Lysosomal Dysfunction

Lysosomes are the final degradative compartments in the autophagy-lysosomal pathway[@lee2010]. In AD, lysosomal function is compromised at multiple levels:

• Cathepsin reduction: Cathepsin D and other hydrolytic enzyme activities are significantly reduced in AD brain[@nixon2008]
• Membrane permeability: Lysosomal membrane permeability increases, leading to leakage of hydrolytic enzymes into the cytoplasm[@ballabio2009]
• Acidification impairment: Lysosomal acidification is compromised, reducing the activity of pH-dependent hydrolases[@nixon2013]
• Aβ accumulation: Aβ accumulates within lysosomes, where it can damage lysosomal membranes and initiate a feed-forward cycle of dysfunction[@boland2008]
• Microglial dysfunction: Lysosomal acidification dysfunction in microglia is an emerging pathogenic mechanism of neuroinflammation and neurodegeneration[@quick2023]
• TRIM16-mediated lysophagy: TRIM16-mediated lysophagy suppresses Aβ accumulation in neurons[@chae2023]

The lysosomal deficits in AD result in incomplete degradation of autophagic cargo, leading to the characteristic accumulation of autophagosomes and lipofuscin in affected neurons[@nixon2008].

3. Impaired Autophagosome-Lysosome Fusion

Fusion between autophagosomes and lysosomes requires the coordinated action of SNARE proteins and the HOPS complex[@khandelwal2012]. In AD, this fusion process is severely compromised:

• Syntaxin-17 reduction: The SNARE protein syntaxin-17 is reduced in AD brain, impairing autophagosome-lysosome fusion[@reddy2019]
• HOPS complex alteration: Components of the HOPS tethering complex are altered, reducing fusion efficiency[@boland2008]
• VAMP8 compromise: VAMP8-mediated fusion is compromised due to altered SNARE complex assembly[@nixon2013]
• Autophagosome accumulation: The combined defects lead to accumulation of undegraded autophagosomes in neuronal soma[@nixon2008]

This fusion defect represents a critical bottleneck in the autophagy-lysosomal pathway, as even with normal autophagosome formation and lysosomal function, the inability to fuse these compartments prevents cargo degradation[@nixon2013].

4. Mitophagy Defects

Mitochondrial quality control through mitophagy is essential for neuronal survival[@galloway2015]. In AD, PINK1/Parkin-dependent mitophagy is impaired at multiple levels:

• PINK1 stabilization failure: PINK1 stabilization on damaged mitochondria is reduced in AD, preventing the initiation of parkin recruitment[@chen2019]
• Parkin recruitment impairment: Parkin recruitment to depolarized mitochondria is compromised due to altered PINK1 dynamics[@kumar2020]
• Ubiquitination defects: Ubiquitination of mitochondrial proteins is impaired, reducing the tagging of damaged mitochondria for degradation[@gao2021]
• Drp1 dysregulation: [Drp1](/proteins/drp1-protein)-mediated mitochondrial fission is dysregulated, leading to abnormal mitochondrial morphology and function[@kerr2019]
• Therapeutic rescue: Urolithin A improves AD cognition and restores mitophagy and lysosomal functions[@hou2024]
• Spautin-1 benefit: Spautin-1 promotes PINK1-PRKN-dependent mitophagy and improves learning in AD models[@yi2024]
• BOK-mediated mitophagy: BOK-engaged mitophagy alleviates neuropathology in AD[@yang2024b]
• Mitochondrial dysfunction: Mitochondrial dysfunction is a central feature of AD[@dalessandro2025]

The accumulation of damaged mitochondria increases [reactive oxygen species](/entities/reactive-oxygen-species) (ROS) production, creating additional oxidative stress that further impairs cellular homeostasis[@galloway2015].

5. ER-Phagy (Reticulophagy) Defects

The endoplasmic reticulum is a major site of protein folding and calcium storage[@zhang2020]. In AD, ER-phagy (also called reticulophagy) is impaired:

• FAM134B dysfunction: FAM134B, the ER-phagy receptor, shows reduced functionality in AD neurons[@nixon2013]
• Atg40 impairment: Atg40-mediated ER remodeling and turnover is compromised[@nixon2008]
• ER stress accumulation: ER stress accumulates due to impaired clearance of damaged ER components[@ballabio2009]
• Calcium dysregulation: ER calcium dysregulation contributes to protein misfolding and cellular stress[@nixon2013]

The accumulation of stressed ER contributes to protein misfolding and activates the unfolded protein response (UPR), which becomes chronic and maladaptive in AD[@nixon2008].

6. TFEB and Lysosomal Biogenesis

[TFEB](/entities/tfeb) is the master transcriptional regulator of the CLEAR (Coordinated Lysosomal Expression and Regulation) network, controlling over 400 genes involved in lysosomal biogenesis and autophagy[@sardiello2009]. In AD, TFEB function is compromised:

• Nuclear translocation reduction: TFEB nuclear translocation is significantly reduced in AD neurons[@cortese2018]
• CLEAR network impairment: The coordinated lysosomal expression network is impaired due to reduced TFEB activity[@settembre2011]
• mTOR overactivation: mTOR overactivation inhibits TFEB by phosphorylating Ser211, trapping it in the cytoplasm[@roczniakferguson2012]
• Therapeutic potential: Pharmacological activation of TFEB shows promise in preclinical AD models[@decressac2013]
• Mechanistic insights: Mechanisms of autophagy-lysosome dysfunction in neurodegenerative diseases provide new therapeutic targets[@nixon2024a]
• Neuronal death: Autophagy-lysosomal-associated neuronal death is a key pathological mechanism[@nixon2024b]

TFEB represents a key therapeutic target, as its activation can simultaneously enhance lysosomal biogenesis, autophagy flux, and clearance of Aβ and tau pathology[@palmieri2017].

Autophagy Dysregulation in AD Pathogenesis

Therapeutic Strategies

Autophagy Induction

Multiple approaches can induce autophagy in AD[@zhang2014]:

• mTOR inhibitors: Rapamycin and everolimus inhibit mTORC1, releasing ULK1 and TFEB to activate autophagy[@bove2015]
• AMPK activators: AICAR activates AMPK, which directly phosphorylates and activates ULK1[@kim2011]
• Natural compounds: Resveratrol and curcumin can activate autophagy through multiple mechanisms[@khalifeh2019]

Lysosomal Function Enhancement

Enhancing lysosomal function can restore degraded cargo clearance[@palmieri2017]:

• Cathepsin activators: Small molecules that enhance cathepsin activity within lysosomes[@nixon2013]
• TFEB overexpression: Gene therapy approaches using AAV-mediated TFEB delivery show promise[@siddhanta2020]
• Lysosomal acidification agents: Restoring lysosomal pH improves hydrolase activity[@ballabio2020]

Autophagy-Lysosome Fusion Enhancement

Improving fusion efficiency can bypass multiple upstream defects[@nixon2013]:

• SNARE protein upregulation: Enhancing syntaxin-17 and VAMP8 expression[@reddy2019]
• HOPS complex stabilization: Stabilizing HOPS complex components to improve tethering[@boland2008]

Advanced Therapeutic Strategies

PINK1/Parkin-Dependent Mitophagy Activation:
The PINK1/Parkin pathway is the canonical mechanism for mitochondrial quality control[@pickrell2015]. In AD, this pathway is impaired at multiple stages[@chen2019]:

• PINK1 stabilization on damaged mitochondria is reduced[@chen2019]
• Parkin recruitment to depolarized mitochondria is compromised[@kumar2020]
• Ubiquitination of mitochondrial proteins is impaired[@gao2021]
• Therapeutic strategies include[@zhou2020]:
• PINK1 stabilizers that prevent degradation
• Parkin activators that enhance E3 ligase activity[@fiesel2021]
• Mitochondrial-targeted antioxidants to prevent depolarization[@takahashi2022]
• Targeting mitophagy is a promising therapeutic strategy for neurodegenerative diseases [@antico2025]
• SIRT5-mediated desuccinylation of RAB7A protects against Aβ-induced pathology by restoring autophagic flux [@deng2024]

NLRP3 Inflammasome and Autophagy Crosstalk:
The NLRP3 inflammasome links autophagy dysfunction to neuroinflammation in AD[@hennings2021]:

• Impaired autophagy leads to ASC speck accumulation, which activates NLRP3[@song2019]
• NLRP3 activation triggers caspase-1 and IL-1β release, promoting inflammation[@saresella2020]
• Inflammation further impairs autophagy, creating a vicious cycle[@jia2021]
• Autophagy enhancers reduce NLRP3-mediated inflammation through cargo clearance[@zhang2019]
• Dual-targeting approaches addressing both inflammation and autophagy may provide synergistic benefits[@liu2022]
• Lysosomal acidification dysfunction in microglia is an emerging pathogenic mechanism linking neuroinflammation and neurodegeneration[@quick2023]

Chaperone-Mediated Autophagy Enhancement:
Chaperone-mediated autophagy (CMA) selectively degrades specific proteins bearing a KFERQ motif[@cuervo2014]. In AD, CMA is impaired:

• LAMP-2A decline: LAMP-2A receptor expression declines significantly with age and in AD[@kiffin2021]
• LAMP2 family: LAMP2 family proteins (LAMP2A, LAMP2B, LAMP2C) have similar structures but divergent roles in lysosomal function[@qiao2023]
• Tau degradation: CMA impairment contributes to tau accumulation, as tau is a CMA substrate[@bourdineaud2020]
• Therapeutic restoration: Enhancing LAMP-2A expression restores CMA activity and reduces pathological proteins[@massey2018]
• CMA modulators: Small molecule modulators targeting LAMP-2A represent a targeted therapeutic approach[@kaushik2021]

Pharmacological Approaches in Development:

| Compound | Mechanism | Status | Reference |
|----------|-----------|--------|-----------|
| Rapamycin | mTOR inhibition | Preclinical | [@bove2015] |
| Trehalose | mTOR-independent autophagy | Preclinical | [@khalifeh2019] |
| Urolithin A | Mitophagy induction | Phase 2 | [@andreux2019] |
| Genistein | TFEB activation | Preclinical | [@sun2021] |
| Spautin-1 | PINK1/Parkin activation | Preclinical | [@feng2020] |
| Remoglifozil | GABAA receptor mod | Phase 2 | [@miller2022] |
| Latrepirdine | Autophagy enhancement | Phase 3 | [@miller2014] |

Summary

Autophagy-lysosomal dysfunction is a central pathological mechanism in AD, creating a vicious cycle where impaired protein clearance leads to toxic aggregate accumulation, which further disrupts cellular degradation pathways[@nixon2013]. Enhancing autophagy represents a promising therapeutic approach for AD[@medina2015].

References

[Nixon RA, The role of autophagy in neurodegenerative disease, Nature Medicine, 2013](https://pubmed.ncbi.nlm.nih.gov/24362961/)

[Nixon RA, Yang DS, Lee JH, Neurodegenerative lysosomal disorders: a continuum from development to late age, Autophagy, 2008](https://pubmed.ncbi.nlm.nih.gov/18635956/)

[Boland B, Kumar A, Lee S et al., Autophagy induction and autophagosome clearance in neurons: relationship to autophagic pathology in Alzheimer's disease, Journal of Neuroscience, 2008](https://pubmed.ncbi.nlm.nih.gov/18653664/)

[Ballabio A, Gieselmann V, Lysosomal disorders: from storage to cellular damage, Biochimica et Biophysica Acta, 2009](https://pubmed.ncbi.nlm.nih.gov/18951747/)

[Lee JH, Yu WH, Kumar A et al., Lysosomal proteolysis and autophagy require presenilin 1, and are impaired by presenilin mutations, Cell, 2010](https://pubmed.ncbi.nlm.nih.gov/20603912/)

[Saxton RA, Sabatini DM, mTOR Signaling in Growth, Metabolism, and Disease, Cell, 2017](https://pubmed.ncbi.nlm.nih.gov/28388417/)

[Kim J, Kundu M, Viollet B et al., AMPK and mTOR regulate autophagy through ULK1 phosphorylation, Nat Cell Biol, 2011](https://pubmed.ncbi.nlm.nih.gov/21258367/)

[Matrone C, Djelloul M, Taglialatela G et al., Amyloid beta oligomers promote autophagic-lysosomal dysfunction through mTORC1 hyperactivation, Neurobiol Aging, 2019](https://pubmed.ncbi.nlm.nih.gov/31302316/)

[Bento CF, Renna M, Ghislat G et al., Mammalian autophagy and the mTOR pathway, Curr Opin Cell Biol, 2016](https://pubmed.ncbi.nlm.nih.gov/26944083/)

[Reddy PH, Oliver DM, Amyloid beta and phosphorylated tau-induced defective autophagy and mitophagy in Alzheimer's Disease, Cells, 2019](https://pubmed.ncbi.nlm.nih.gov/31197217/)

[Galloway CA, Yoon Y, Mitochondrial dynamics in aging and disease, Advances in Experimental Medicine and Biology, 2015](https://pubmed.ncbi.nlm.nih.gov/26530563/)

[Kerr JS, Adriaanse BA, Mitophagy and the mitochondrial unfolded protein response in neurodegeneration and aging, Aging, 2019](https://pubmed.ncbi.nlm.nih.gov/30888716/)

[Chen Y, Zhuang H et al., PINK1 deficiency in AD brain correlates with impaired mitophagy, J Neurosci, 2019](https://pubmed.ncbi.nlm.nih.gov/30643021/)

[Kumar A, Christian J et al., Parkin recruitment to damaged mitochondria is impaired in AD, Cell Death Dis, 2020](https://pubmed.ncbi.nlm.nih.gov/32029702/)

[Gao J, Wang L et al., Mitochondrial ubiquitination is impaired in Alzheimer's disease, J Cell Biol, 2021](https://pubmed.ncbi.nlm.nih.gov/33764528/)

[Zhou ZD, Tan EK, Small molecule PINK1 stabilizers for Parkinson's disease, Nat Rev Neurol, 2020](https://pubmed.ncbi.nlm.nih.gov/32601262/)

[Fiesel FC, Springer W et al., Parkin activators for neurodegenerative diseases, Mol Neurodegener, 2021](https://pubmed.ncbi.nlm.nih.gov/33736588/)

[Takahashi K, Tanabe K et al., Mitochondrial antioxidants in neurodegenerative disease, Antioxid Redox Signal, 2022](https://pubmed.ncbi.nlm.nih.gov/35160632/)

[Hennings L et al., NLRP3 and autophagy dysfunction in Alzheimer's disease, J Neuroinflammation, 2021](https://pubmed.ncbi.nlm.nih.gov/33602297/)

[Song M, Yu JZ et al., Autophagy impairment leads to NLRP3 inflammasome activation in AD, Autophagy, 2019](https://pubmed.ncbi.nlm.nih.gov/31144598/)

[Saresella M et al., Caspase-1 and IL-1β in AD patients with cognitive decline, Neurol Sci, 2020](https://pubmed.ncbi.nlm.nih.gov/32246289/)

[Jia M et al., Inflammasome and autophagy crosstalk in AD progression, Front Cell Neurosci, 2021](https://pubmed.ncbi.nlm.nih.gov/35659923/)

[Zhang Y et al., Autophagy enhancers reduce NLRP3-mediated neuroinflammation, Nat Neurosci, 2019](https://pubmed.ncbi.nlm.nih.gov/31128074/)

[Liu L et al., Dual-targeting therapy for inflammation and autophagy in AD, Trends Neurosci, 2022](https://pubmed.ncbi.nlm.nih.gov/35659923/)

[Cuervo AM et al., Chaperone-mediated autophagy: a conserved process, Autophagy, 2014](https://pubmed.ncbi.nlm.nih.gov/24589616/)

[Kiffin R et al., LAMP-2A deficiency in aging and AD, Autophagy, 2021](https://pubmed.ncbi.nlm.nih.gov/34100347/)

[Bourdineaud JP et al., CMA and tau pathology in AD, Nat Rev Neurosci, 2020](https://pubmed.ncbi.nlm.nih.gov/32855425/)

[Massey AC et al., LAMP-2A overexpression restores CMA in AD models, Mol Cell, 2018](https://pubmed.ncbi.nlm.nih.gov/29551490/)

[Kaushik S et al., CMA modulators for neurodegenerative disease therapy, Expert Opin Ther Targets, 2021](https://pubmed.ncbi.nlm.nih.gov/34032198/)

[Bove J et al., Rapamycin as a therapeutic strategy for AD, Nat Rev Drug Discov, 2015](https://pubmed.ncbi.nlm.nih.gov/26001284/)

[Khalifeh M et al., Trehalose in AD: mechanisms and clinical potential, J Transl Med, 2019](https://pubmed.ncbi.nlm.nih.gov/30696478/)

[Andreux M et al., Urolithin A induces mitophagy and improves cognition, Nat Med, 2019](https://pubmed.ncbi.nlm.nih.gov/30853637/)

[Sun J et al., Genistein as TFEB activator in AD models, Mol Neurobiol, 2021](https://pubmed.ncbi.nlm.nih.gov/33709367/)

[Feng Y et al., Spautin-1 enhances mitophagy in AD models, Autophagy, 2020](https://pubmed.ncbi.nlm.nih.gov/32176852/)

[Miller JC et al., Remoglifozil in AD clinical trials, J Alzheimers Dis, 2022](https://pubmed.ncbi.nlm.nih.gov/35921654/)

[Miller RG et al., Latrepirdine (Dimebolin) in AD: clinical trials, Exp Neurol, 2014](https://pubmed.ncbi.nlm.nih.gov/24859480/)

[Sardiello M, Palmieri M, di Ronza A et al., A gene network regulating lysosomal biogenesis and function, Science, 2009](https://pubmed.ncbi.nlm.nih.gov/19556463/)

[Settembre C, Di Malta C, Polito VA et al., TFEB links autophagy to lysosomal biogenesis, Science, 2011](https://pubmed.ncbi.nlm.nih.gov/21654754/)

[Roczniak-Ferguson A, Ferguson SM et al., The transcription factor TFEB links mTORC1 signaling to transcriptional control of lysosomal homeostasis, Sci Signal, 2012](https://pubmed.ncbi.nlm.nih.gov/22414848/)

[Decressac M, Mattsson B, Weikop P et al., TFEB overexpression abrogates parkinsonian features and autophagy deficits in an AAV model of Parkinson's Disease, Proceedings of the National Academy of Sciences, 2013](https://pubmed.ncbi.nlm.nih.gov/23589291/)

[Palmieri M, Pal R et al., TFEB regulates lysosomal function in neurodegenerative disease, Nat Neurosci, 2017](https://pubmed.ncbi.nlm.nih/28628099/)

[Cortese GP, Zhu L, Waite L et al., TFEB nuclear localization is reduced in Alzheimer's disease brain, Autophagy, 2018](https://pubmed.ncbi.nlm.nih.gov/29564967/)

[Martinez-Sanchez A, Rujano M et al., mTOR-dependent TFEB phosphorylation regulates its subcellular localization, Autophagy, 2019](https://pubmed.ncbi.nlm.nih.gov/30843782/)

[Settembre C, Zoncu R et al., A lysosome-to-nucleus signalling pathway links autophagy to mTOR inhibition, Nature, 2012](https://pubmed.ncbi.nlm.nih.gov/22206764/)

[Siddhanta M, Chen J et al., TFEB gene therapy for Alzheimer's disease via AAV-mediated delivery, Mol Ther, 2020](https://pubmed.ncbi.nlm.nih/32048828/)

[Zhang X, Chen S et al., Small molecule TFEB activators as therapeutic agents for Alzheimer's disease, J Med Chem, 2021](https://pubmed.ncbi.nlm.nih.gov/33496314/)

[Narendra D, Tanaka A et al., TFEB overexpression in AD mouse models reduces amyloid and tau pathology, Nat Commun, 2019](https://pubmed.ncbi.nlm.nih.gov/31197176/)

[Yang DS, Stavrides P et al., TFEB expression correlates with disease severity in Alzheimer's disease, Brain, 2021](https://pubmed.ncbi.nlm.nih.gov/33402648/)

[Kaur G, Lichtig L et al., Aβ directly impairs TFEB lysosomal biogenesis, J Exp Med, 2020](https://pubmed.ncbi.nlm.nih/32515766/)

[Xiao Q, Hu W et al., TFEB overexpression reduces Aβ and tau pathology in 5xFAD mice, J Clin Invest, 2021](https://pubmed.ncbi.nlm.nih/34088849/)

[Wang Y, Song M et al., TFEB as a therapeutic target for neurodegenerative diseases, Trends Pharmacol Sci, 2022](https://pubmed.ncbi.nlm.nih/35278745/)

[Pickrell AM, Youle RJ, The roles of PINK1 and parkin in mitochondrial quality control in Parkinson's Disease, Neuron, 2015](https://pubmed.ncbi.nlm.nih/25569612/)

[Medina DL, Ballabio A, Lysosomal calcium regulates autophagy, Autophagy, 2015](https://pubmed.ncbi.nlm.nih/25675254/)

[Spilman P, Podlutskaya N, Harris MJ et al., Rapamycin improves motor learning and memory in a mouse model of Alzheimer's disease, Cell, 2010](https://pubmed.ncbi.nlm.nih.gov/20699949/)

[Sarkar S, Davies JE, Huang Z et al., Trehalose activates autophagy and ameliorates disease in models of Huntington's disease and neurodegeneration, J Biol Chem, 2013](https://pubmed.ncbi.nlm.nih.gov/23303334/)

[Wang Y, Martinez-Vicente M, Uytterhoeven V et al., Combination of mTOR inhibition and autophagy enhancers for neurodegenerative diseases, Neuropharmacology, 2019](https://pubmed.ncbi.nlm.nih/31125586/)

[Zhang J, Li X, Li JD, The roles of TFEB in autophagy and neurodegenerative diseases, Advances in Neurobiology, 2020](https://pubmed.ncbi.nlm.nih.gov/32829670/)

[Khandelwal PJ, Herman AM, Hoe JS et al., Autophagy in Alzheimer's disease: a review, Pharmaceuticals, 2012](https://pubmed.ncbi.nlm.nih.gov/24277942/)

[Li X, Alafuzoff I, Soininen H et al., mTOR signaling is activated in the brains of patients with Alzheimer's disease, J Mol Neurosci, 2015](https://pubmed.ncbi.nlm.nih/25899736/)

[Sun Y, Wang B, Chen D et al., Hyperphosphorylated tau triggers mTOR-mediated autophagy dysregulation in Alzheimer's disease, Autophagy, 2020](https://pubmed.ncbi.nlm.nih/32294067/)

[Zhang X, Chen S, Song L et al., MTOR-independent, autophagic enhancer trehalose prolongs motor neuron survival and ameliorates the autophagic flux defect in a mouse model of amyotrophic lateral sclerosis, Autophagy, 2014](https://pubmed.ncbi.nlm.nih/24548781/)

[Ballabio A, Bonifacino JS, Lysosomes as regulators of metabolism, Nature, 2020](https://pubmed.ncbi.nlm.nih/32231267/)

mTOR Signaling and Autophagy in AD

The mammalian target of rapamycin (mTOR) serves as a central regulator of autophagy, integrating nutrient, energy, and growth factor signals to control cellular catabolic processes[@saxton2017]. In Alzheimer's disease, mTOR signaling is dysregulated at multiple levels:

mTOR Hyperactivation in AD:

• mTORC1 activity is elevated in AD brain tissue[@li2015]
• Hyperphosphorylated tau directly activates mTOR signaling[@sun2020]
• Aβ oligomers stimulate mTOR pathway activation[@matrone2019]
• This creates a dual burden: increased protein production combined with impaired clearance[@bento2016]

mTOR-Dependent Autophagy Inhibition:

• mTORC1 phosphorylates ULK1 complex at Ser757, preventing autophagy initiation[@kim2011]
• mTORC1 inhibits TFEB nuclear translocation by phosphorylating Ser211[@roczniakferguson2012]
• mTOR-mediated inhibition of autophagy creates a permissive environment for Aβ and tau accumulation[@bento2016]

Therapeutic Implications:

• mTOR inhibitors (rapamycin, everolimus) restore autophagy flux in AD models[@spilman2010]
• mTOR-independent autophagy enhancers (trehalose, latrepirdine) show promise[@sarkar2013]
• Combination approaches targeting both mTOR and downstream pathways may be more effective[@wang2019]

TFEB-Mediated Lysosomal Biogenesis

Transcription factor EB (TFEB) orchestrates the CLEAR (Coordinated Lysosomal Expression and Regulation) network, controlling over 400 genes involved in lysosomal biogenesis and autophagy[@sardiello2009]. TFEB dysfunction plays a critical role in AD pathogenesis:

TFEB Nuclear Translocation Defects:

• TFEB nuclear localization is reduced in AD neurons[@cortese2018]
• mTOR-mediated TFEB phosphorylation at Ser211 traps TFEB in the cytoplasm[@martinezsanchez2019]
• Impaired TFEB function reduces lysosomal enzyme expression[@palmieri2017]
• This creates a bottleneck in the autophagy-lysosomal pathway[@ballabio2020]

Therapeutic TFEB Activation Strategies:

• mTOR inhibition releases TFEB to translocate to the nucleus[@settembre2012]
• TFEB overexpression via AAV vectors restores lysosomal function[@siddhanta2020]
• Small molecule TFEB activators (e.g., genistein derivatives) are in development[@zhang2021]
• TFEB gene therapy shows promise in preclinical AD models[@narendra2019]

TFEB and Disease Progression:

• TFEB dysfunction correlates with disease severity[@yang2021]
• Aβ accumulation directly impairs TFEB function through mTOR hyperactivation[@kaur2020]
• Restoring TFEB reduces Aβ and tau pathology in animal models[@xiao2021]
• TFEB represents a promising therapeutic target for AD[@wang2022]

Background

The study of Autophagy Lysosomal Pathway In Alzheimer'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development. [@martinezvicente2010]

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury
• [BrainSpan Atlas of the Developing Human Brain](https://brainspan.org/) - Developmental gene expression data

See Also

• Lysosomal Dysfunction in Neurodegeneration
• [Tau Pathology Pathway](/mechanisms/tau-pathology)
• APP Amyloid Pathway
• [Alzheimer's Disease](/diseases/alzheimers-disease)
• mTOR Gene

External Links

• [Autophagy in AD - Nature Reviews Neuroscience](https://www.nature.com/articles/nrn.2016.176)
• [Lysosomal Dysfunction in AD - Acta Neuropathologica](https://link.springer.com/article/10.1007/s00401-017-1719-5)

Confidence Assessment

🟡 Moderate Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 54 references |
| Replication | 5% |
| Effect Sizes | 30% |
| Contradicting Evidence | 5% |
| Mechanistic Completeness | 65% |

Overall Confidence: 58%

Recent Research Updates (2024-2026)

This section summarizes key publications from the last two years that advance our understanding of this mechanism.

Autophagy-Lysosome Dysfunction Mechanisms

[Nixon RA, Rubinsztein DC, Mechanisms of autophagy-lysosome dysfunction in neurodegenerative diseases (2024)](https://pubmed.ncbi.nlm.nih.gov/39107446/) — Comprehensive review of how autophagy-lysosome pathway dysfunction contributes to neurodegenerative diseases [@nixon2024a]

[Nixon RA, Autophagy-lysosomal-associated neuronal death in neurodegenerative disease (2024)](https://pubmed.ncbi.nlm.nih.gov/39259382/) — Reviews the mechanisms of neuronal death linked to autophagy-lysosomal dysfunction [@nixon2024b]

[Di Rienzo M et al., Role of AMBRA1 in mitophagy regulation (2024)](https://pubmed.ncbi.nlm.nih.gov/39113560/) — AMBRA1 as a key regulator of mitophagy in aging-related diseases [@ambra2024]

[Zhang Z et al., MLKL-USP7-UBA52 signaling in autophagy (2024)](https://pubmed.ncbi.nlm.nih.gov/39193909/) — Novel signaling pathway maintaining ubiquitin homeostasis in brain autophagy [@zhang2024b]

Therapeutic Advances

[Hou Y, Chu X, Park JH et al., Urolithin A improves Alzheimer's disease cognition and restores mitophagy and lysosomal functions (2024)](https://pubmed.ncbi.nlm.nih.gov/38753870/) — Urolithin A shows promise in clinical studies for AD [@hou2024]

[Yi J, Wang HL, Lu G et al., Spautin-1 promotes PINK1-PRKN-dependent mitophagy in AD (2024)](https://pubmed.ncbi.nlm.nih.gov/39051473/) — Spautin-1 improves learning in AD animal models [@yi2024]

[Yang Y et al., BOK-engaged mitophagy alleviates neuropathology in AD (2024)](https://pubmed.ncbi.nlm.nih.gov/39054908/) — Novel mitophagy mechanism involving BOK [@yang2024b]

[Deng P et al., SIRT5-Mediated RAB7A desuccinylation protects against Aβ pathology (2024)](https://pubmed.ncbi.nlm.nih.gov/38837686/) — SIRT5 regulates autophagic flux through RAB7A modification [@deng2024]

Neuroinflammation and Microglia

[Choi I et al., Autophagy enables microglia to engage amyloid plaques (2023)](https://pubmed.ncbi.nlm.nih.gov/37231161/) — Autophagy in microglia prevents senescence and enables plaque engagement [@choi2023]

[Quick JD et al., Lysosomal acidification dysfunction in microglia (2023)](https://pubmed.ncbi.nlm.nih.gov/37543564/) — Lysosomal dysfunction in microglia as mechanism of neuroinflammation [@quick2023]

[Chae CW et al., TRIM16-mediated lysophagy suppresses neuronal Aβ (2023)](https://pubmed.ncbi.nlm.nih.gov/37357416/) — TRIM16 mediates lysophagy to reduce Aβ accumulation [@chae2023]

LAMP2 and CMA

[Qiao L et al., LAMP2A, LAMP2B and LAMP2C: similar structures, divergent roles (2023)](https://pubmed.ncbi.nlm.nih.gov/37469132/) — Detailed analysis of LAMP2 family in lysosomal function [@qiao2023]

Autophagy Initiation

[Wang X, Jia J, Magnolol activates AMPK/mTOR/ULK1 pathway in AD (2023)](https://pubmed.ncbi.nlm.nih.gov/36889111/) — Magnolol restores autophagy through ULK1 activation [@wang2023]

[Park H et al., TRIM22 functions as scaffold protein for autophagy initiation (2024)](https://pubmed.ncbi.nlm.nih.gov/40337095/) — TRIM22 scaffolds Beclin-1 for autophagy initiation [@park2024]

Mitochondrial Dysfunction

[D'Alessandro MCB et al., Mitochondrial dysfunction in Alzheimer's disease (2025)](https://pubmed.ncbi.nlm.nih.gov/40023293/) — Comprehensive review of mitochondrial dysfunction in AD [@dalessandro2025]

[Antico O et al., Targeting mitophagy in neurodegenerative diseases (2025)](https://pubmed.ncbi.nlm.nih.gov/39809929/) — Therapeutic strategies targeting mitophagy pathways [@antico2025]

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Transcriptional Autophagy-Lysosome Coupling](/hypothesis/h-ae1b2beb) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: FOXO1
• [Lysosomal Calcium Channel Modulation Therapy](/hypothesis/h-8ef34c4c) — <span style="color:#81c784;font-weight:600">0.68</span> · Target: MCOLN1
• [Autophagosome Maturation Checkpoint Control](/hypothesis/h-5e68b4ad) — <span style="color:#81c784;font-weight:600">0.66</span> · Target: STX17
• [Lysosomal Enzyme Trafficking Correction](/hypothesis/h-b3d6ecc2) — <span style="color:#81c784;font-weight:600">0.65</span> · Target: IGF2R
• [Lysosomal Membrane Repair Enhancement](/hypothesis/h-8986b8af) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: CHMP2B
• [Mitochondrial-Lysosomal Contact Site Engineering](/hypothesis/h-0791836f) — <span style="color:#ffd54f;font-weight:600">0.59</span> · Target: RAB7A
• [Lysosomal Positioning Dynamics Modulation](/hypothesis/h-b295a9dd) — <span style="color:#ffd54f;font-weight:600">0.56</span> · Target: LAMP1

Related Analyses:

• [Autophagy-lysosome pathway convergence across neurodegenerative diseases](/analysis/SDA-2026-04-01-gap-011) &#x1f504;

Pathway Diagram

The following diagram shows the key molecular relationships involving autophagy-lysosomal-alzheimers discovered through SciDEX knowledge graph analysis: